Endocrine Abstracts

JOINT1194

Introduction: Chronic kidney disease (CKD) is one of the most common comorbid conditions in patients with metabolic syndrome. Early detection of CKD may help to improve therapeutic approaches and thus prevent disease progression and complications.

Aim: To determine the incidence of metabolic disorders in patients with subclinical albuminuria (AU).

Materials and Methods: AURA (NCT05690009) is a registry of real clinical practice in 34 regions of the Russian Federation, including 4531 patients over 40 years of age without previously diagnosed CKD, type 1 or type 2 diabetes mellitus. AU levels were measured once using test strips during the period of enrolling patients in the register. The threshold value for AU was defined as 20 mg/l. All enrolled patients were divided into 2 groups according to test result for comparative analyses.

Results: AU levels <20 mg/l were detected in 1592 patients (35.1%), whereas AU levels ≥20 mg/l were detected in 2939 patients (64.9%). Diagnostically relevant AU was more common in men (44.2% (≥20 mg/l) vs 38.6% (<20 mg/l); P < 0.001), in those who were overweight (28.1 vs 27.2 kg/m²; P < 0.001) and in smokers (19.1% vs 15.7%; P = 0.006). Among chronic diseases, metabolic syndrome (32.0% vs 23.4%; P < 0.001), hypertension (79.0% vs 71.5%; P < 0.001) and prediabetes (14.7% vs 8.9%; P < 0.001) were significantly more reported. Among laboratory markers, serum uric acid levels were found to be higher in patients with AU (316 [259;383] vs 298 [246;357] µmol/l; P < 0.001). AU was not associated with the presence of dyslipidemia (low-density lipoproteins (3.1 [2.3; 3.9] vs 3.1 [2.3; 3.9] mmol/l; P = 0.901). However, a significant association was observed between albuminuria and high-density lipoproteins (1.3 vs. 1.4 mmol/l; P < 0.001) and triglycerides (1.4 vs. 1.3 mmol/l; P = 0.002). The multivariate model revealed that the detection of AU ≥20 mg/l was significantly influenced by age, and the presence of metabolic syndrome, prediabetes and cardiovascular disease (Table 1).

Conclusion: The AURA registry has demonstrated that subclinical AU is directly associated with a number of cardiometabolic factors. Therefore, for individuals with prediabetes and metabolic syndrome, determining their AU using test strips can serve as an effective screening method for early CKD detection. This approach will enhance the delivery of medical care and facilitate timely nephroprotection.